Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARG | P13631 | 17/20 | 0.69 |
| ▸ | RARB | P10826 | 12/20 | 0.69 |
| ▸ | RXRA | P19793 | 2/20 | 0.69 |
| ▸ | RARA | P10276 | 12/20 | 0.60 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5847741 | 0.88 | RARG (0.53) | RARGRARBRXRARARACYP3A4 | |
| SCHEMBL5846137 | 0.88 | RARG (0.77) | RARGRARBRXRARARA | |
| SCHEMBL5846380 | 0.83 | RARG (0.78) | RARGRARBRXRARARA | |
| SCHEMBL5846332 | 0.83 | RARG (0.68) | RARGRARBRXRARARACYP26A1 | |
| SCHEMBL8343465 | 0.82 | RARG (0.65) | RARGRARBRXRARARA | |
| SCHEMBL2915270 | 0.82 | RARG (0.69) | RARGRARBRXRARARA | |
| SCHEMBL5846151 | 0.82 | RARG (0.62) | RARGRARBRXRARARA | |
| SCHEMBL5846642 | 0.81 | RARB (0.82) | RARGRARBRXRARARA | |
| SCHEMBL5846349 | 0.81 | RARG (0.44) | RARGRARBRXRARARA | |
| SCHEMBL5846718 | 0.81 | RARG (0.43) | RARGRARBRXRARARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040030141-A1 | Biphenyl derivatives substituted with an aromatic or heteroaromatic radical, and pharmaceutical and cosmetic compositions containing them | GALDERMA RESEARCH & DEVELOPMENT | 2004-02-12 | — | — | US | claimed |
| EP-0952974-B1 | BIPHENYL DERIVATIVES SUBSTITUTED BY AN AROMATIC OR HETEROAROMATIC RADICAL AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME | GALDERMA RES & DEV (FR) | 2001-11-21 | — | — | EP | claimed |
| US-7148245-B2 | Biphenyl derivatives substituted with an aromatic or heteroaromatic radical, and pharmaceutical and cosmetic compositions containing them | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2006-12-12 | — | — | US | disclosed |
| US-20040030141-A1 | Biphenyl derivatives substituted with an aromatic or heteroaromatic radical, and pharmaceutical and cosmetic compositions containing them | GALDERMA RESEARCH & DEVELOPMENT | 2004-02-12 | — | — | US | disclosed |
| US-6649612-B1 | Combating skin ageing and keratinization | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-11-18 | — | — | US | disclosed |
| EP-0952974-B1 | BIPHENYL DERIVATIVES SUBSTITUTED BY AN AROMATIC OR HETEROAROMATIC RADICAL AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME | GALDERMA RES & DEV (FR) | 2001-11-21 | — | — | EP | disclosed |
| US-6316009-B1 | FOR THERAPY OF DERMATOLOGICAL COMPLAINTS ASSOCIATED WITH A KERATINIZATION DISORDER, AND FOR COMBATING AGEING OF THE SKIN | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2001-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040030141-A1 | Biphenyl derivatives substituted with an aromatic or heteroaromatic radical, and pharmaceutical and cosmetic compositions containing them | AHR, TYR, CYP1A1 | RARG 39/4885RARB 26/4885RXRA 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.